Drug Profile
Research programme: Staphylococcus aureus vaccine - Syntiron/Sanofi
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Syntiron
- Developer Sanofi
- Class Bacterial vaccines; Conjugate vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Staphylococcal-infections(Prevention) in Europe
- 28 Feb 2022 No recent reports of development identified for preclinical development in Staphylococcal-infections(Prevention) in USA
- 23 Jan 2018 Syntiron receives a National Institutes of Health grant for its Staphylococcus aureus vaccine development programme (Syntiron pipeline, January 2018)